Country: Malta
Language: English
Source: Malta Medicines Authority
PharmaPath S.A. 28is Oktovriou 1, Agia Varvara, 123 51, , Greece
B01AF02
APIXABAN 5 mg
FILM-COATED TABLET
APIXABAN 5 mg
POM
ANTITHROMBOTIC AGENTS
Authorised
2023-08-21
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT APIXERIN 2.5 MG FILM-COATED TABLETS APIXERIN 5 MG FILM-COATED TABLETS apixaban READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Apixerin is and what it is used for 2. What you need to know before you take Apixerin 3. How to take Apixerin 4. Possible side effects 5. How to store Apixerin 6. Contents of the pack and other information 1. WHAT APIXERIN IS AND WHAT IT IS USED FOR Apixerin contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting. _ _ Apixerin is used in adults: _Apixerin 2.5 mg film-coated tablets:_ - to prevent blood clots (deep vein thrombosis [DVT]) from forming after hip or knee replacement operations. After an operation to the hip or knee you may be at a higher risk of developing blood clots in your leg veins. This can cause the legs to swell, with or without pain. If a blood clot travels from your leg to your lungs, it can block blood flow causing breathlessness, with or without chest pain. This condition (pulmonary embolism) can be life- threatening and requires immediate medical attention. - to prevent a blood clot from forming in the heart in patients with an irregular heartbeat (atrial fibrillation) and at least one additional risk factor. Blood clots may break off and travel to the brain and lead to a stroke or to other organs and prevent normal bl Read the complete document
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Apixerin 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg of apixaban. Excipient(s) with known effect Each 5 mg film-coated tablet contains 104.4 mg lactose (see section 4.4). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) Pink, oval film-coated tablets with dimensions 10.0 mm x 5.2 mm approximately. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _ _ Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) _ The recommended dose of apixaban is 5 mg taken orally twice daily. _Dose reduction _ The recommended dose of apixaban is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL (133 micromole/L). Therapy should be continued long-term. _Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) _ The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation). 2 The recommended dose of apixaban for the prevention of recurrent DVT and PE Read the complete document